MX2016010875A - Compuesto de triazina y su uso para propositos medicos. - Google Patents
Compuesto de triazina y su uso para propositos medicos.Info
- Publication number
- MX2016010875A MX2016010875A MX2016010875A MX2016010875A MX2016010875A MX 2016010875 A MX2016010875 A MX 2016010875A MX 2016010875 A MX2016010875 A MX 2016010875A MX 2016010875 A MX2016010875 A MX 2016010875A MX 2016010875 A MX2016010875 A MX 2016010875A
- Authority
- MX
- Mexico
- Prior art keywords
- triazine compound
- medical purposes
- compound
- mpges
- rheumatism
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporciona un compuesto que tiene una actividad inhibidora de mPGES-1 y que es de utilidad para la prevención o el tratamiento de dolor, reumatismo, osteoartritis, fiebre, enfermedad de Alzheimer, esclerosis múltiple, arteriosclerosis, glaucoma, hipertensión ocular, enfermedad retinal isquémica, esclerodermia sistémica y cáncer, incluyendo cáncer colorrectal; un compuesto representado por la fórmula [I] o una de sus sales farmacéuticamente aceptables: (ver Fórmula) en donde cada símbolo es como se define en la memoria descriptiva.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014031035 | 2014-02-20 | ||
PCT/JP2015/054519 WO2015125842A1 (ja) | 2014-02-20 | 2015-02-19 | トリアジン化合物及びその医薬用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016010875A true MX2016010875A (es) | 2016-10-26 |
MX369217B MX369217B (es) | 2019-10-31 |
Family
ID=53878341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016010875A MX369217B (es) | 2014-02-20 | 2015-02-19 | Compuesto de triazina y su uso para propositos medicos. |
Country Status (31)
Country | Link |
---|---|
US (3) | US20150266834A1 (es) |
EP (2) | EP3109240B1 (es) |
JP (4) | JP6461637B2 (es) |
KR (1) | KR102360699B1 (es) |
CN (1) | CN106232585B (es) |
AR (1) | AR099498A1 (es) |
AU (1) | AU2015219920B2 (es) |
BR (1) | BR112016018341B1 (es) |
CA (1) | CA2936408C (es) |
CL (1) | CL2016002091A1 (es) |
CY (1) | CY1121261T1 (es) |
DK (1) | DK3109240T3 (es) |
ES (1) | ES2704922T3 (es) |
HR (1) | HRP20182134T1 (es) |
IL (1) | IL247319B (es) |
LT (1) | LT3109240T (es) |
MX (1) | MX369217B (es) |
MY (1) | MY183605A (es) |
PE (2) | PE20211548A1 (es) |
PH (1) | PH12016501651B1 (es) |
PL (1) | PL3109240T3 (es) |
PT (1) | PT3109240T (es) |
RS (1) | RS58235B1 (es) |
RU (1) | RU2692789C2 (es) |
SA (1) | SA516371701B1 (es) |
SG (1) | SG11201606902QA (es) |
SI (1) | SI3109240T1 (es) |
TR (1) | TR201821158T4 (es) |
TW (1) | TWI651310B (es) |
WO (1) | WO2015125842A1 (es) |
ZA (1) | ZA201606449B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI651310B (zh) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
CA2972366C (en) * | 2014-12-24 | 2020-04-21 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
US11078412B2 (en) * | 2015-03-04 | 2021-08-03 | Shimadzu Corporation | Polyamine and tyramine analysis method using pyrene containing fluorescence derivatization reagent and excimer fluorescence |
EP4046991A1 (en) * | 2015-08-17 | 2022-08-24 | Japan Tobacco Inc. | Hydroxytriazine compounds and pharmaceutical use thereof |
JP6817952B2 (ja) * | 2015-10-29 | 2021-01-20 | あすか製薬株式会社 | ピリミジン誘導体 |
GB201603311D0 (en) * | 2016-02-25 | 2016-04-13 | Jakobsson Per Johan | New uses and methods |
KR102503590B1 (ko) * | 2016-08-01 | 2023-02-24 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
CN110799506B (zh) * | 2017-06-26 | 2024-03-01 | 默克专利有限公司 | 用于制备被取代的含氮杂环化合物的方法 |
US20220281841A1 (en) * | 2019-07-22 | 2022-09-08 | Angion Biomedica Corp. | Ethynylheterocycles as rho-associated coiled-coil kinase (rock) inhibitors |
US11786538B2 (en) * | 2019-12-11 | 2023-10-17 | Somerset Therapeutics, Llc | Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties |
KR102157466B1 (ko) * | 2020-05-19 | 2020-09-17 | 동아대학교 산학협력단 | 헥사하이드로트리아진 유도체를 포함하는 방광암의 예방, 개선 또는 치료용 조성물 |
EP4289832A1 (en) | 2021-02-02 | 2023-12-13 | ASKA Pharmaceutical Co., Ltd. | Pyrimidine derivative |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1981003020A1 (en) * | 1980-04-22 | 1981-10-29 | Commw Scient Ind Res Org | Triazine synthesis |
DE19543730A1 (de) * | 1995-11-23 | 1997-05-28 | Ciba Geigy Ag | Bis-Resorcinyl-Triazine |
AR038955A1 (es) * | 1996-12-05 | 2005-02-02 | Amgen Inc | Compuestos de pirimidinona y piridona sustituidos y metodos para su uso |
BR9713850A (pt) * | 1996-12-05 | 2000-02-29 | Amgen Inc | Composto, composição farmacêutica, processos para profilaxia ou tratamento de infecção e de doenças, para diminuir concentrações no plasma de qualquer um ou de ambos tnf-. e o;-1 de qualquer um ou de ambos il-6 e il-8, para profilaxia ou tratamento da doença diabetes e de um distúrbio da dor em um mamìfero, para dimunuir a produção de prostaglandinas em um mamìfero, e, para dimuir a atividade da enzima ciclooxigenase em um mamìfero. |
AU2003245669A1 (en) * | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
EP2138488A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
CN101747282A (zh) * | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
CA2811154C (en) * | 2009-09-23 | 2019-01-08 | Albert Einstein College Of Medicine Of Yeshiva University | Prostaglandin transporter inhibitors and uses thereof |
AR086254A1 (es) * | 2011-05-26 | 2013-11-27 | Lilly Co Eli | Derivados de imidazol utiles para el tratamiento de artritis |
FR2983859B1 (fr) * | 2011-12-12 | 2014-01-17 | Sanofi Sa | Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique |
CN104114543B (zh) * | 2012-01-06 | 2019-03-15 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
TWI568722B (zh) * | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
JP2014031035A (ja) | 2012-08-01 | 2014-02-20 | Yamaha Motor Co Ltd | 原動機付き鞍乗型車両 |
TWI651310B (zh) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
CN105586773A (zh) * | 2014-11-13 | 2016-05-18 | 东丽纤维研究所(中国)有限公司 | 一种拒水抗紫外纺织品及其生产方法和用途 |
-
2015
- 2015-02-17 TW TW104105551A patent/TWI651310B/zh active
- 2015-02-19 CN CN201580020793.6A patent/CN106232585B/zh active Active
- 2015-02-19 PT PT15751885T patent/PT3109240T/pt unknown
- 2015-02-19 SI SI201530563T patent/SI3109240T1/sl unknown
- 2015-02-19 EP EP15751885.3A patent/EP3109240B1/en active Active
- 2015-02-19 EP EP18201469.6A patent/EP3456713A1/en not_active Withdrawn
- 2015-02-19 MY MYPI2016703028A patent/MY183605A/en unknown
- 2015-02-19 US US14/626,243 patent/US20150266834A1/en not_active Abandoned
- 2015-02-19 LT LTEP15751885.3T patent/LT3109240T/lt unknown
- 2015-02-19 RS RS20181563A patent/RS58235B1/sr unknown
- 2015-02-19 KR KR1020167025241A patent/KR102360699B1/ko active IP Right Grant
- 2015-02-19 ES ES15751885T patent/ES2704922T3/es active Active
- 2015-02-19 MX MX2016010875A patent/MX369217B/es active IP Right Grant
- 2015-02-19 CA CA2936408A patent/CA2936408C/en active Active
- 2015-02-19 SG SG11201606902QA patent/SG11201606902QA/en unknown
- 2015-02-19 PE PE2021000546A patent/PE20211548A1/es unknown
- 2015-02-19 AR ARP150100484A patent/AR099498A1/es active IP Right Grant
- 2015-02-19 PE PE2016001506A patent/PE20161236A1/es unknown
- 2015-02-19 JP JP2015030157A patent/JP6461637B2/ja active Active
- 2015-02-19 WO PCT/JP2015/054519 patent/WO2015125842A1/ja active Application Filing
- 2015-02-19 TR TR2018/21158T patent/TR201821158T4/tr unknown
- 2015-02-19 PL PL15751885T patent/PL3109240T3/pl unknown
- 2015-02-19 DK DK15751885.3T patent/DK3109240T3/en active
- 2015-02-19 RU RU2016137263A patent/RU2692789C2/ru active
- 2015-02-19 BR BR112016018341-0A patent/BR112016018341B1/pt active IP Right Grant
- 2015-02-19 AU AU2015219920A patent/AU2015219920B2/en active Active
-
2016
- 2016-08-17 IL IL24731916A patent/IL247319B/en active IP Right Grant
- 2016-08-18 PH PH12016501651A patent/PH12016501651B1/en unknown
- 2016-08-18 SA SA516371701A patent/SA516371701B1/ar unknown
- 2016-08-18 CL CL2016002091A patent/CL2016002091A1/es unknown
- 2016-09-19 ZA ZA2016/06449A patent/ZA201606449B/en unknown
-
2018
- 2018-12-17 HR HRP20182134TT patent/HRP20182134T1/hr unknown
- 2018-12-19 CY CY20181101359T patent/CY1121261T1/el unknown
- 2018-12-26 JP JP2018241974A patent/JP2019065036A/ja active Pending
-
2019
- 2019-04-26 US US16/396,503 patent/US20200087266A1/en not_active Abandoned
-
2021
- 2021-01-05 JP JP2021000347A patent/JP2021054856A/ja not_active Ceased
-
2022
- 2022-01-14 US US17/575,931 patent/US20230011968A1/en active Pending
- 2022-06-17 JP JP2022097960A patent/JP2022120173A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501651A1 (en) | Triazine compound and use thereof for medical purposes | |
PH12020551305A1 (en) | Pharmaceutical Compounds | |
SG11201806930PA (en) | Novel condensed pyrimidine compound or salt thereof | |
GEP20217248B (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
CA2925624C (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
TN2018000218A1 (en) | Indole carboxamides compounds useful as kinase inhibitors. | |
EA201991693A1 (ru) | Производное пиридина в качестве ингибитора ask1 и способ его получения и применения | |
WO2016198531A3 (en) | Hpv vaccines | |
PH12020550503A1 (en) | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors | |
EA201591291A1 (ru) | Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания | |
PH12017500095A1 (en) | Imidazopyridazine compounds | |
WO2016004404A3 (en) | Gls1 inhibitors for treating disease | |
JO3789B1 (ar) | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة | |
CY1120836T1 (el) | Ενωσεις 1,3,4-θειαδιαζοαης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
WO2016004413A3 (en) | Gls1 inhibitors for treating disease | |
PH12018500181A1 (en) | Hydroxytriazine compound and medical use thereof | |
MX2019002369A (es) | Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial. | |
PH12015502744A1 (en) | Bicyclic nitrogen-containing aromatic heterocyclic amide compound | |
MX2018011592A (es) | Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo. | |
WO2015155680A3 (en) | Pyrazole derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors | |
PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
PH12016502432A1 (en) | 1h-1,8-naphthyridin-2-ones as anti proliferative compounds | |
PH12016501645A1 (en) | Aminopyrazolone derivative | |
MX2021014093A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
PH12019502792A1 (en) | Tetrahydropyridopyrazine modulators of gpr6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |